Refers to a compound of formula I or II where R1 is naftiridin [1,5] - 2 - (methyl), quinazolin IL - 2 - yl) methyl], among others R2 is 3 - (R) - 1 - amino - piperidin YL,(2 - amino - 2 - Methyl Propyl - (methylamino) or (S) - 2 - amino - propyl) - methylamino.Preferred compounds are: 1 - [(4 - methyl - 2 - quinazolin - yl) methyl] - 3 - methyl - 4 - (2 - BUTYN - 1 - 8 (IL -) - 3 - (R) - amino - piperidin-1-yl) - xanthine 1 - [[(15] - naftiridin - 2 - yl) methyl] - 3 - methyl - 4 - (2 - BUTYN - 1 - 8 (IL -) - (R) - 3 - amino - piperidin-1-yl) - xanthine among others. It also relates to a Pharmaceutical Composition and a preparation method.The described compounds are inhibitors of DPP IV, useful in the treatment of Diabetic Foot ulcer associated with diabetic dyslipidemia, hyperlipidemia, diabetes, heart failureSE REFIERE A UN COMPUESTO DE FORMULA I o II DONDE R1 ES [1,5]NAFTIRIDIN-2-IL)METILO, (QUINAZOLIN-2-IL)METILO], ENTRE OTROS R2 ES 3-(R)-AMINO-PIPERIDIN-1-ILO,(2-AMINO-2-METIL-PROPIL)-METILAMINO o (2-(S)-AMINO-PROPIL)-METILAMINO. SON COMPUESTOS PREFERIDOS : 1-[(4-METIL-QUINAZOLIN-2-IL)METIL]-3-METIL-7-(2-BUTIN-1-IL)-8-(3-(R)-AMINO-PIPERIDIN-1-IL)-XANTINA 1-[([1,5]-NAFTIRIDIN-2-IL)METIL]-3-METIL-7-(2-BUTIN-1-IL)-8-((R)-3-AMINO-PIPERIDIN-1-IL)-XANTINA ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. LOS COMPUESTOS DESCRITOS SON INHIBIDORES DE DPP IV, UTILES EN EL TRATAMIENTO DE PIE DIABETICO, ULCERA ASOCIADA A DIABETES, HIPERLIPIDEMIA, DISLIPIDEMIA DIABETICA, INSUFICIENCIA CARDIACA
